Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Atom Bioscience’s Novel Gout Therapy Meets Efficacy Endpoint

publication date: Mar 23, 2022

Jiangsu Atom Bioscience reported its treatment for gout met its primary efficacy endpoint in a double-blind placebo-controlled Phase IIa trial. ABP-671 is a small molecule inhibitor of the urate transporter protein that increases the excretion of uric acid to prevent gout attacks. Atom says ABP-671 reduced serum uric acid levels  to less than 6 mg/dL, below the clinically defined threshold of 7 mg/dL, without showing any serious safety concerns. Earlier this year, Atom Bio closed a $45 million Series C financing to support a global Phase III clinical trial of ABP-671. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital